



(51) International Patent Classification:

C07C 201/10 (2006.01) C07C 205/12 (2006.01)

(21) International Application Number:

PCT/US2022/019573

(22) International Filing Date:

09 March 2022 (09.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/159,227 10 March 2021 (10.03.2021) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: CAILLE, Sebastien; c/o Amgen Inc., Law Dept – Patent Ops, Mail Stop 28-5-A, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). MURRAY, James; c/o Amgen Inc., Law Dept – Patent Ops, Mail Stop 28-5-A, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). QUASDORF, Kyle; c/o Amgen Inc., Law Dept – Patent Ops, Mail Stop 28-5-A, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). NGUYEN, Hannah; c/o Amgen Inc.,

Law Dept – Patent Ops, Mail Stop 28-5-A, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). SILVA ELIPE, Maria Victoria; c/o Amgen Inc., Law Dept – Patent Ops, Mail Stop 28-5-A, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). ERICSON, Ari Elizabeth; c/o Amgen Inc., Law Dept – Patent Ops, Mail Stop 28-5-A, One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(74) Agent: ZHONG, Qiwen et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: SYNTHESIS OF OMECAMTIV MECARBIL




FIGURE 1

Process flow diagram (PFD) for LDA preparation

(57) Abstract: Provided herein are synthetic methods for the preparation of intermediates that are utilized in the synthesis of omeamtiv mecarbil dihydrochloride.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*